Driving Out Chronic Lymphocytic Leukemia With CAR T Cells

•High-risk chronic lymphocytic leukemia (CLL) continues to pose a therapeutic challenge.•Responses to chimeric antigen receptor (CAR) T cell therapy have been impressive even in high-risk CLL.•If granted Food and Drug Administration approval, CAR T cell therapy could be considered in pathway inhibitor failure.•Off-the-shelf CAR T cell products offer the option of more readily available therapies.